Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Heidelberg, Universität Heidelberg, Dissertation, 2019
- Schlagwort
-
Neuroblastoma
Risk
Example
Comprehension
Krebsforschung
Neuroblastom
Molekularbiologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Heidelberg
- (wer)
-
Universitätsbibliothek Heidelberg
- (wann)
-
2021
- Urheber
- Beteiligte Personen und Organisationen
- DOI
-
10.11588/heidok.00026558
- URN
-
urn:nbn:de:bsz:16-heidok-265586
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:46 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Blatter, Mona Soledad
- Höfer, Thomas
- Universitätsbibliothek Heidelberg
Entstanden
- 2021
Ähnliche Objekte (12)
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
Exploiting tumour addiction with a serine and glycine-free diet
Functional validation of novel target structures for treatment of high-risk neuroblastoma
AEROSOL ADDICTION
Time Addiction
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Reward processing in obesity, substance addiction and non-substance addiction
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
Exploiting tumour addiction with a serine and glycine-free diet
Functional validation of novel target structures for treatment of high-risk neuroblastoma
AEROSOL ADDICTION
Time Addiction
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Reward processing in obesity, substance addiction and non-substance addiction
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
Exploiting tumour addiction with a serine and glycine-free diet
Functional validation of novel target structures for treatment of high-risk neuroblastoma
AEROSOL ADDICTION
Time Addiction
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)